(Reuters) -Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share. Metsera's board has recommended that its shareholders "approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer." (Reporting by Rishabh Jaiswal in Bengaluru; Editing by Leslie Adler and Thomas Derpinghaus)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Kolkata (West Bengal) [India], February 14– Exide Industries Limited has launched the Exide Diksha Scholarship,…
New Delhi, [India], February 14: The National Conference on “Mission Viksit Bharat @2047: Through Comprehensive Socio-Economic…
Bengaluru (Karnataka) [India], February 14: Happyyou 24/7, a digital mental health initiative by Basilmind Private…
Mumbai (Maharashtra) [India], February 14: A petition challenging WeWork India’s initial public offering prospectus has…
Mumbai (Maharashtra) [India], February 14: ATLAS SkillTech University and ISDI – School of Design & Innovation,…
New Delhi [India], February 13: At a time when India’s legal discourse is often reactive,…